UNSPSC 51142014: Sodium thiosalicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H5O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2D9ITW04B, chemically known as 2-mercapto-benzoic acid, monosodium salt but generally known as sodium thiosalicylate, which bears US NIH Compound Identifier 8636. European Medicines Agency schedules Sodium thiosalicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15331MIG.

As of Q4 2014, SODIUM THIOSALICYLATE remains the US FDA Preferred Term for this commodity. Sodium thiosalicylate bears US NLM identifiers UMLS ID C0304347 and NCI Concept Code C87326. SMILES: SC1C(CCCC1)C(=O)O.[NA].

UNSPSC 51142014 Sodium thiosalicylate is a Commodity code that in recent state and local procurement activity has been applied to pharmaceutical and healthcare product procurement, though the tagging appears misaligned with the code's nominal chemical compound scope. The recent opportunities solicited under this code show state and local health agencies, county health departments, and multistate cooperative purchasing entities buying naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and formal RFP processes. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations administered by state departments of administration (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These entities are procuring products for community health initiatives, pharmacy benefit programs, and government employee and retiree health plans.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with MMCAP serving as a regional aggregation vehicle for multiple participating states and local jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. Winning vendors in the MMCAP procurement face a 3 percent administrative fee on all purchases and performance penalties of $200 to $1,500 per violation, with contract terms of two years for new responders and optional extensions at MMCAP's sole discretion.